Pharmacokinetics, Safety, and Tolerability of a 2-Month Dose Interval Regimen of the Long-Acting Injectable Antipsychotic Aripiprazole Lauroxil: Results From a 44-Week Phase I Study

BACKGROUND: Aripiprazole lauroxil (AL) is a long-acting injectable antipsychotic approved for treatment of schizophrenia in adults. Approved AL doses and dosing regimens include 441 mg monthly, 662 mg monthly, and 882 mg monthly or every 6 weeks (q6wk), as well as the most recently approved dose, 10...

Descripción completa

Detalles Bibliográficos
Autores principales: Weiden, Peter J., Du, Yangchun, von Moltke, Lisa, Wehr, Angela, Hard, Marjie, Marandi, Morteza, Walling, David P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2020
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7447659/
https://www.ncbi.nlm.nih.gov/pubmed/32621071
http://dx.doi.org/10.1007/s40263-020-00745-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7447659/
https://www.ncbi.nlm.nih.gov/pubmed/32621071
http://dx.doi.org/10.1007/s40263-020-00745-1

Ejemplares similares